| $337M | ||
| $259M | ||
| $100M | ||
| $79M | ||
| $60M | ||
| $58M |
Buys | $0 | 0 | 0 |
Sells | $394,112 | 13 | 100 |
| Ferguson Toby | Chief Medical Officer | 0 | $0 | 1 | $34,595 | $-34,595 |
| Carter Todd Alfred | Chief Scientific Officer | 0 | $0 | 3 | $44,277 | $-44,277 |
| Fahey Sandell Jacquelyn | Chief Legal Officer | 0 | $0 | 2 | $54,307 | $-54,307 |
| Swartz Robin | COO&CBO | 0 | $0 | 4 | $99,915 | $-99,915 |
| Sandrock Alfred | President & CEO | 0 | $0 | 3 | $161,018 | $-161,018 |
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Over the last 12 months, insiders at Voyager Therapeutics, Inc. have bought $0 and sold $394,112 worth of Voyager Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Voyager Therapeutics, Inc. have bought $20.58M and sold $3.79M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 4,395,588 shares for transaction amount of $39.03M was made by NEUROCRINE BIOSCIENCES INC (10 percent owner) on 2023‑02‑23.
| 2025-04-02 | Sale | Sandrock Alfred | President and CEO | 10,885 0.0198% | $3.43 | $37,336 | -5.87% | |
| 2025-04-02 | Sale | Ferguson Toby | Chief Medical Officer | 10,086 0.0184% | $3.43 | $34,595 | -5.87% | |
| 2025-02-20 | Sale | Sandrock Alfred | President and CEO | 11,702 0.0211% | $4.24 | $49,616 | -20.89% | |
| 2025-02-20 | Sale | Swartz Robin | COO & CBO | 3,894 0.007% | $4.25 | $16,550 | -20.89% | |
| 2025-02-20 | Sale | Carter Todd Alfred | Chief Scientific Officer | 3,305 0.006% | $4.26 | $14,079 | -20.89% | |
| 2025-02-11 | Sale | Sandrock Alfred | President & CEO | 16,644 0.0255% | $4.45 | $74,066 | -19.71% | |
| 2025-02-11 | Sale | Swartz Robin | COO & CBO | 6,950 0.0106% | $4.45 | $30,928 | -19.71% | |
| 2025-02-11 | Sale | Fahey Sandell Jacquelyn | Chief Legal Officer | 4,358 0.0067% | $4.45 | $19,393 | -19.71% | |
| 2025-02-11 | Sale | Carter Todd Alfred | Chief Scientific Officer | 5,413 0.0083% | $4.45 | $24,088 | -19.71% | |
| 2025-01-14 | Sale | Swartz Robin | COO & CBO | 3,087 0.0057% | $5.09 | $15,713 | -30.89% | |
| 2025-01-14 | Sale | Carter Todd Alfred | Chief Scientific Officer | 1,191 0.0022% | $5.13 | $6,110 | -30.89% | |
| 2024-12-23 | Sale | Swartz Robin | COO&CBO | 6,500 0.0117% | $5.65 | $36,725 | -37.87% | |
| 2024-10-02 | Sale | Fahey Sandell Jacquelyn | Chief Legal Officer | 5,999 0.0109% | $5.82 | $34,914 | -27.58% | |
| 2024-04-02 | Sale | Sandrock Alfred | President and CEO | 12,115 0.0222% | $9.86 | $119,454 | -33.10% | |
| 2024-04-02 | Sale | Swartz Robin | Chief Operating Officer | 1,357 0.0025% | $9.88 | $13,407 | -33.10% | |
| 2024-02-21 | Sale | Sandrock Alfred | President and CEO | 13,033 0.0278% | $7.46 | $97,226 | -7.33% | |
| 2024-02-21 | Sale | PFREUNDSCHUH PETER P. | Chief Financial Officer | 3,764 0.008% | $7.46 | $28,079 | -7.33% | |
| 2024-02-21 | Sale | Swartz Robin | Chief Operating Officer | 3,966 0.0084% | $7.45 | $29,547 | -7.33% | |
| 2024-02-21 | Sale | Carter Todd Alfred | Chief Scientific Officer | 3,365 0.0072% | $7.47 | $25,137 | -7.33% | |
| 2024-02-20 | Sale | Carter Todd Alfred | Chief Scientific Officer | 602 0.0013% | $7.68 | $4,623 | -6.21% |
| Sandrock Alfred | President and CEO | 430931 0.7787% | $1.5M | 0 | 6 | |
| Ferguson Toby | Chief Medical Officer | 157914 0.2854% | $551,119.86 | 0 | 1 | |
| Swartz Robin | COO & CBO | 98397 0.1778% | $343,405.53 | 0 | 12 | |
| Fahey Sandell Jacquelyn | Chief Legal Officer | 81643 0.1475% | $284,934.07 | 0 | 2 | |
| Carter Todd Alfred | Chief Scientific Officer | 77718 0.1404% | $271,235.82 | 0 | 13 | |
| NEUROCRINE BIOSCIENCES INC | 10 percent owner | 8575316 15.4967% | $29.93M | 2 | 0 | +7.14% |
| TEPPER ROBERT I | 5428933 9.8108% | $18.95M | 0 | 3 | ||
| Third Rock Ventures III, L.P. | 10 percent owner | 4685291 8.4669% | $16.35M | 0 | 8 | |
| EcoR1 Capital, LLC | director | 3851507 6.9602% | $13.44M | 1 | 3 | +28.87% |
| Sanofi | 2477941 4.478% | $8.65M | 1 | 0 | <0.0001% | |
| PAUL STEVEN M | President and CEO | 872351 1.5765% | $3.04M | 1 | 0 | <0.0001% |
| PFREUNDSCHUH PETER P. | Chief Financial Officer | 175669 0.3175% | $613,084.81 | 0 | 2 | |
| Turenne Andre | President & CEO | 148375 0.2681% | $517,828.75 | 0 | 3 | |
| Sah Dinah Ph.D. | Chief Scientific Officer | 138688 0.2506% | $484,021.12 | 0 | 1 | |
| Khwaja Omar | See remarks | 120509 0.2178% | $420,576.41 | 0 | 3 | |
| Hesslein Robert W. | Senior VP & General Counsel | 106610 0.1927% | $372,068.90 | 0 | 10 | |
| GERAGHTY JAMES A | director | 76588 0.1384% | $267,292.12 | 2 | 0 | <0.0001% |
| Burek Julie | VP, Finance | 52458 0.0948% | $183,078.42 | 0 | 5 | |
| Dorval Allison | Chief Financial Officer | 45894 0.0829% | $160,170.06 | 0 | 3 | |
| Higgins Michael J | 31314 0.0566% | $109,285.86 | 0 | 1 | ||
| Ottmer Matthew P. | Chief Operating Officer | 26276 0.0475% | $91,703.24 | 0 | 1 | |
| PIERCE GLENN | 16788 0.0303% | $58,590.12 | 1 | 1 | <0.0001% | |
| Henderson Jane | Sr. V.P. & CFO, Corp. Dev. | 0 0% | $0 | 0 | 4 | |
| Ravina Bernard | Chief Medical Officer | 0 0% | $0 | 0 | 10 |
$22,617,831 | 95 | 3.32% | $158.86M | |
$7,237,838 | 92 | -8.14% | $164.64M | |
$140,938,207 | 36 | 14.75% | $193.56M | |
$18,752,549 | 33 | -28.39% | $159.06M | |
$63,049,419 | 31 | 2.87% | $208.65M | |
$79,019,806 | 27 | 7.24% | $216.41M | |
$41,069,367 | 23 | 54.64% | $197.49M | |
$178,593,887 | 15 | -14.86% | $163.2M | |
$15,799,576 | 12 | -39.52% | $204.8M | |
$1,229,070 | 10 | 23.53% | $213.86M | |
Voyager Therapeutics, Inc. (VYGR) | $145,296,407 | 8 | -0.98% | $193.12M |
$17,675,244 | 7 | 92.20% | $168.27M | |
$45,000,000 | 6 | -31.22% | $160.65M | |
$88,549,962 | 5 | -16.91% | $198.27M | |
$32,289,200 | 3 | -5.46% | $160.99M | |
$40,000,000 | 3 | -16.24% | $194.98M | |
$149,309 | 3 | 6.07% | $169.16M | |
$9,999,990 | 1 | 32.51% | $211.66M | |
$20,020,000 | 1 | -75.24% | $174.17M |
| Increased Positions | 48 | +28.74% | 2M | +6.6% |
| Decreased Positions | 68 | -40.72% | 2M | -5.96% |
| New Positions | 12 | New | 269,080 | New |
| Sold Out Positions | 28 | Sold Out | 1M | Sold Out |
| Total Postitions | 147 | -11.98% | 35M | +0.64% |
| Blackrock, Inc. | $19,701.00 | 9.84% | 5.41M | +55,501 | +1.04% | 2025-03-31 |
| Armistice Capital, Llc | $19,641.00 | 9.81% | 5.4M | +196,000 | +3.77% | 2024-12-31 |
| Ecor1 Capital, Llc | $14,260.00 | 7.12% | 3.92M | 0 | 0% | 2024-12-31 |
| Vanguard Group Inc | $11,704.00 | 5.85% | 3.22M | +29,014 | +0.91% | 2024-12-31 |
| Farallon Capital Management Llc | $9,357.00 | 4.67% | 2.57M | +278,700 | +12.16% | 2024-12-31 |
| Dimensional Fund Advisors Lp | $5,025.00 | 2.51% | 1.38M | +275,571 | +24.94% | 2024-12-31 |
| Vestal Point Capital, Lp | $4,477.00 | 2.24% | 1.23M | +740,000 | +151.02% | 2024-12-31 |
| Geode Capital Management, Llc | $3,947.00 | 1.97% | 1.08M | +4,729 | +0.44% | 2024-12-31 |
| Erste Asset Management Gmbh | $3,852.00 | 1.92% | 1.06M | 0 | 0% | 2024-12-31 |
| State Street Corp | $3,279.00 | 1.64% | 900,932 | +8,189 | +0.92% | 2024-12-31 |